Prostate cancer is the most common invasive cancer in men. Radical prostatectomy (RP) is a definitive treatment option, but biochemical recurrence can reach 40%. Salvage lymphadenectomy is a relatively recent approach to oligometasis and has been rapidly diffused primarily due to improvement in imaging diagnosis and results showing possibly promising therapy.
Serum cancer biomarker has been proven to be very valuable in cancer diagnosis, disease monitoring and prognosis assessment, despite there is still a lack of serum biomarker for penile cancer (PC). Our initial analysis on public GEO dataset identified CCL20 as a top C-C motif ligand (CCL) gene enriched in PC.
Urothelial carcinoma is the sixth most common cancer type in the United States. Although most patients present with early stage disease which is associated with improved outcomes, many will progress to locally advanced or metastatic disease.
According to The Cancer Genome Atlas (TCGA), around 9% of bladder carcinomas usually show abnormalities of the murine double minute 2 (MDM2) gene, but a few studies have been investigated them. We profiled MDM2 gene amplification in a series of urothelial carcinomas (UC) considering the molecular subtypes and expression of programmed death ligand 1 (PD-L1).
Lymph node dissection is an indispensable component of radical cystectomy for bladder cancer. Information obtained with lymph node dissection is highly predictive of patient survival, affecting decision-making for adjuvant therapy (diagnostic role).
Nonmuscle-invasive bladder cancer (NMIBC) has heterogeneous recurrence and progression outcomes. Available risk calculators estimate recurrence and progression but do not predict the recurrence stage or grade, which may influence downstream treatment.
Sexual difficulties are one of the most common, distressing, and persistent treatment-related challenges for men diagnosed with prostate cancer, often under-recognized and poorly managed. Many men who have received prostate cancer treatment have unmet sexual care needs that remain over time, with these needs further exacerbated by men’s reluctance to seek help for their sexual […]
Alicia Morgans: Hi, my name is Alicia Morgans. I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago, in the United States. I’m so excited to have here with me today, Dr. Karim Fizazi, who’s a GU medical oncologist and a professor of oncology at Gustave Roussy in Paris, France. […]
Carcinoma in situ (CIS) of the urothelium within the bladder or upper tract is a highly progressive disease when left untreated. Topical therapy with Bacillus Calmette-Guérin (BCG) has been a mainstay of treatment both within the bladder and upper tracts. Patients who fail BCG therapy are left with limited options and are recommended for cystectomy […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so thrilled and honored to have here with me today some good friends and colleagues to speak about the HERO data. First, we’ll start with having my co-moderator, Dr. Mike Cookson introduce […]
